» Articles » PMID: 35900161

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Treatment of Anxiety, Obsessive-compulsive and Posttraumatic Stress Disorders - Version 3. Part I: Anxiety Disorders

Abstract

Aim: This is the third version of the guideline of the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders (published in 2002, revised in 2008).

Method: A consensus panel of 33 international experts representing 22 countries developed recommendations based on efficacy and acceptability of available treatments. In total, 1007 RCTs for the treatment of these disorders in adults, adolescents, and children with medications, psychotherapy and other non-pharmacological interventions were evaluated, applying the same rigorous methods that are standard for the assessment of medications.

Result: This paper, Part I, contains recommendations for the treatment of panic disorder/agoraphobia (PDA), generalised anxiety disorder (GAD), social anxiety disorder (SAD), specific phobias, mixed anxiety disorders in children and adolescents, separation anxiety and selective mutism. Selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are first-line medications. Cognitive behavioural therapy (CBT) is the first-line psychotherapy for anxiety disorders. The expert panel also made recommendations for patients not responding to standard treatments and recommendations against interventions with insufficient evidence.

Conclusion: It is the goal of this initiative to provide treatment guidance for these disorders that has validity throughout the world.

Citing Articles

Pharmacogenetic Testing in Treatment-resistant Panic Disorder: a Preliminary Analysis.

Fidry M, Zugliani M, do Cabo M, Martins R, Gomez M, Faria C Clin Pract Epidemiol Ment Health. 2025; 20():e17450179337258.

PMID: 39839219 PMC: 11748058. DOI: 10.2174/0117450179337258241031035148.


Impact of psychotropic pro re nata prescription-monitoring programme on prescriptions for inpatients with psychiatric disorders: a retrospective observational study.

Saito Y, Sumida K, Muraoka H, Oishi S, Suzuki R, Nishikawa T BMC Psychiatry. 2025; 25(1):46.

PMID: 39825279 PMC: 11742780. DOI: 10.1186/s12888-025-06508-w.


A distributed subcortical circuit linked to instrumental information-seeking about threat.

Trier H, Khalighinejad N, Hamilton S, Harbison C, Priestley L, Laubach M Proc Natl Acad Sci U S A. 2025; 122(3):e2410955121.

PMID: 39813246 PMC: 11761969. DOI: 10.1073/pnas.2410955121.


Racial/ethnic differences in mental health treatment received among people with comorbid cardiometabolic and depressive symptomology: National Health and Nutrition Examination Survey, 2017 to March 2020 Pre-Pandemic.

Dark T, Harris R, Burns D, Chernicky J, Reid-Marks L, Rust G PLoS One. 2025; 20(1):e0316430.

PMID: 39746015 PMC: 11695010. DOI: 10.1371/journal.pone.0316430.


Depression and anxiety management in cirrhosis.

Zimbrean P, Jakab S Hepatol Commun. 2024; 9(1).

PMID: 39670879 PMC: 11637748. DOI: 10.1097/HC9.0000000000000600.